⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 23, 2025Open Access

Supplementary Figure S3 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma

Michelle Choe Danielle Kirkey Isabel Lira Grace Hawkins Melia Blankenfeld Sarah J. Menashe Rhonda E. Ries Brianna Wrightson Christina Root Cyd N. McKay Jack H. Peplinski Raisa Glabman Lara E. Davis Sanjay V. Malhotra Richard Görlick Elizabeth T. Loggers Soheil Meshinchi

View Full Paper

Ask AI

Bookmark

Share

Key Points

Chimeric antigen receptor T cells targeting folate receptor-α show significant antitumor activity against osteosarcoma.
The findings reveal a notable expression of FOLR1 in normal tissues, raising considerations for treatment safety.
Preclinical evaluation confirms the potential of folate receptor-α CAR T cells to combat osteosarcoma effectively.
These results suggest that targeting FOLR1 could provide an innovative therapeutic approach for osteosarcoma treatment.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Preclinical evaluation shows potent antitumor activity in osteosarcoma models, suggesting FOLR1 targeting is promising.

Abstract

Supplementary Figure S3. Expression of FOLR1 in normal tissues.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Choe et al. (2025) studied this question.

synapsesocial.com/papers/68d6d8978b2b6861e4c3eb7c https://doi.org/10.1158/2767-9764.30186173

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025
2Supplementary Figure S4 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025
3Supplementary Figure S5 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025
4Supplementary Figure S1 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025
5Figure 5 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025

More related papers

Figure 1 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025
Figure 2 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025
Figure 6 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025